328 related articles for article (PubMed ID: 32440215)
1. Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.
Cumbo C; Anelli L; Specchia G; Albano F
Cancer Manag Res; 2020; 12():3175-3189. PubMed ID: 32440215
[TBL] [Abstract][Full Text] [Related]
2. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
3. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
4. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
Alikian M; Gale RP; Apperley JF; Foroni L
Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
[TBL] [Abstract][Full Text] [Related]
5. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.
Cumbo C; Impera L; Minervini CF; Orsini P; Anelli L; Zagaria A; Coccaro N; Tota G; Minervini A; Casieri P; Brunetti C; Rossi AR; Parciante E; Specchia G; Albano F
Oncotarget; 2018 Feb; 9(13):10978-10986. PubMed ID: 29541390
[TBL] [Abstract][Full Text] [Related]
6. Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia.
Löf L; Arngården L; Olsson-Strömberg U; Siart B; Jansson M; Dahlin JS; Thörn I; Christiansson L; Hermansson M; Larsson A; Ahlstrand E; Wålinder G; Söderberg O; Rosenquist R; Landegren U; Kamali-Moghaddam M
Sci Rep; 2017 Apr; 7(1):623. PubMed ID: 28377570
[TBL] [Abstract][Full Text] [Related]
7. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
Moore FR; Rempfer CB; Press RD
Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR).
Abruzzese E; Bocchia M; Trawinska MM; Raspadori D; Bondanini F; Sicuranza A; Pacelli P; Re F; Cavalleri A; Farina M; Malagola M; Russo D; De Fabritiis P; Bernardi S
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627140
[TBL] [Abstract][Full Text] [Related]
9. Current developments in molecular monitoring in chronic myeloid leukemia.
Marum JE; Branford S
Ther Adv Hematol; 2016 Oct; 7(5):237-251. PubMed ID: 27695615
[TBL] [Abstract][Full Text] [Related]
10.
Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.
Tang GS; Wu J; Liu M; Chen H; Gong SG; Yang JM; Hu XX; Wang JM
Am J Transl Res; 2015; 7(3):632-9. PubMed ID: 26045902
[TBL] [Abstract][Full Text] [Related]
12. Exploration of treatment-free remission in CML, based on molecular monitoring.
Zhang Z; Zhou X; Zhou X; Cheng Z; Hu Y
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38133525
[TBL] [Abstract][Full Text] [Related]
13. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
14. Droplet Digital PCR for
Bochicchio MT; Petiti J; Berchialla P; Izzo B; Giugliano E; Ottaviani E; Errichiello S; Rege-Cambrin G; Venturi C; Luciano L; Daraio F; Calistri D; Rosti G; Saglio G; Martinelli G; Pane F; Cilloni D; Gottardi EM; Fava C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771634
[No Abstract] [Full Text] [Related]
15. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring of chronic myeloid leukemia: present and future.
Yeung CC; Egan D; Radich JP
Expert Rev Mol Diagn; 2016 Oct; 16(10):1083-1091. PubMed ID: 27552202
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease Eradication in CML: Does It Really Matter?
Tantravahi SK; Guthula RS; O'Hare T; Deininger MW
Curr Hematol Malig Rep; 2017 Oct; 12(5):495-505. PubMed ID: 28852963
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR can provide improved
Smitalova D; Dvorakova D; Racil Z; Romzova M
Pract Lab Med; 2021 May; 25():e00210. PubMed ID: 33778144
[No Abstract] [Full Text] [Related]
20. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
